Shares in Amgen were down nearly 7% after close of trading yesterday after the company’s heart failure drug omecamtiv mecarbil disappointed in a large phase 3 trial.

A Phase 3 clinical trial investigating Elevidys (delandistrogene ... with patients often succumbing to respiratory and cardiac failure by their early 20s. Approximately 15,000 of the U.S ...

Bayer has added another phase 3 trial into its registration ... signalling growing confidence in a drug that generated mixed results in phase 2. The new OCEANIC-AFINA study will enrol patients ...

In a significant advancement for Parkinson's disease (PD) treatment, NeuroDerm Ltd., a subsidiary of Mitsubishi Tanabe Pharma Corporation, has unveiled the results of the Phase 3 BouNDless trial ...

Notably, the successful completion of the FDA End of Phase ... the drug’s favorable cardiac efficacy. This positions Altimmune advantageously against competitors, with no significant safety concerns.

A new type of targeted medicine has shown ‘remarkable’ benefits for patients with advanced breast cancer in a major phase III clinical trial. The drug capivasertib combined with hormone therapy ...

The first patients have been dosed in three global, randomized phase 3 trials evaluating the efficacy and safety of datopotamab deruxtecan (Dato-DXd)- ...

Otsuka Pharmaceutical’s kidney disease drug has hit the primary endpoint of a phase 3 trial by ... data from this trial suggest that by targeting APRIL, we could provide a new therapeutic ...

Three phase 3 trials of combinations including datopotamab deruxtecan for the treatment of non–small cell lung cancer are beginning.

This is a clinical setting with a patient population where PD-1 monoclonal antibodies have previously been unsuccessful in Phase III global clinical trials ... important new drugs to patients ...

For more information on Cardiol Therapeutics and the PRISM Emerging Biotech Index, visit prismmarketview.com.